ReviewJournal of hepatocellular carcinoma2025
Advancing Hepatocellular Carcinoma Therapy with Next-Generation Molecular and Immunotherapeutics.
Review in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a major global health concern due to its high incidence and mortality rates. Driven by factors such as chronic hepatitis B and C infections, alcohol-related liver disease, and metabolic-associated fatty liver disease (MAFLD), HCC is often diagnosed at advanced stages, limiting therapeutic options and prognosis. Recent advances in understanding the molecular mechanisms and tumor microenvironment of HCC, particularly disruptions in key pathways like Ras-Raf-MEK, PI3K-Akt/mTOR, and Wnt/β-catenin, have catalyzed the development of novel treatment strategies. This review synthesizes findings from over 80 recent peer-reviewed studies to explore the evolution of HCC therapy, including targeted therapies, immune checkpoint inhibitors, combination regimens, surgical techniques, and locoregional treatments. Special emphasis is placed on the role of tumor immunology, emerging biomarkers, and the impact of precision medicine in tailoring treatment strategies. These innovations collectively offer promising avenues for improving survival and quality of life in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.